Sign in

    Corey Rosenbaum

    Healthcare Equity Research Analyst at Scotiabank

    Corey Rosenbaum is a Healthcare Equity Research Analyst at Scotiabank, specializing in providing research and investment analysis within the healthcare sector. He covers a range of healthcare companies, although details of specific companies and quantitative performance metrics are not publicly available. Rosenbaum began his role at Scotiabank approximately 639 days ago and has since established himself as a key part of the healthcare equity research team, with no previous firm affiliations disclosed in public records. Professional credentials or external recognitions are not referenced in available sources.

    Corey Rosenbaum's questions to VERACYTE (VCYT) leadership

    Corey Rosenbaum's questions to VERACYTE (VCYT) leadership • Q2 2025

    Question

    Corey Rosenbaum of Scotiabank, on for Sung Ji Nam, asked about the specific gross margin benefit expected from transitioning the Afirma test to the V2 Transcriptome platform.

    Answer

    CFO Rebecca Chambers explained that while the move from the NextSeq 500 to the NovaSeq X will create a meaningful reduction in sequencing-related costs over time, the company plans to reinvest these savings back into the business to fund growth initiatives. CEO Marc Stapley added that the transition creates a unified, scalable platform for future tests, including Prosigna.

    Ask Fintool Equity Research AI

    Corey Rosenbaum's questions to Adaptive Biotechnologies (ADPT) leadership

    Corey Rosenbaum's questions to Adaptive Biotechnologies (ADPT) leadership • Q1 2025

    Question

    Corey Rosenbaum, for Sung Ji Nam at Scotiabank, inquired if the upgraded DLBCL assay would alter adoption trends and asked for the mix between late-stage and early-stage trials within the MRD pharma business.

    Answer

    Executive Susan Bobulsky stated the enhanced DLBCL assay is a key driver for adoption, especially in pharma trials focused on end-of-therapy MRD detection. She clarified that the majority of the MRD pharma business, particularly in multiple myeloma which is over 60% of the portfolio, is concentrated in later-stage, registrational trials.

    Ask Fintool Equity Research AI

    Corey Rosenbaum's questions to CASTLE BIOSCIENCES (CSTL) leadership

    Corey Rosenbaum's questions to CASTLE BIOSCIENCES (CSTL) leadership • Q3 2024

    Question

    Corey Rosenbaum, on for Sung Ji Nam, asked about physician feedback and awareness for the TissueCypher test following a recent conference, and the potential impact of recent hurricanes on Q4 results and guidance.

    Answer

    CEO Derek Maetzold stated that resistance to TissueCypher is low and the primary hurdle remains early-stage physician awareness and workflow integration. He explained the test helps rule-in patients for ablation therapy and rule-out unnecessary endoscopies. Regarding hurricanes, he noted a potential Q4 volume impact is already factored into the updated 2024 revenue guidance.

    Ask Fintool Equity Research AI